GABRA5

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gamma-aminobutyric acid (GABA) A receptor, alpha 5
Identifiers
Symbols GABRA5 ; MGC138184
External IDs OMIM137142 MGI95617 HomoloGene20219 IUPHAR: α5 ChEMBL: 5112 GeneCards: GABRA5 Gene
Orthologs
Species Human Mouse
Entrez 2558 110886
Ensembl ENSG00000186297 ENSMUSG00000055078
UniProt P31644 Q8BHJ7
RefSeq (mRNA) NM_000810 NM_176942
RefSeq (protein) NP_000801 NP_795916
Location (UCSC) Chr 15:
27.11 – 27.19 Mb
Chr 7:
57.41 – 57.51 Mb
PubMed search [1] [2]

Gamma-aminobutyric acid (GABA) A receptor, alpha 5, also known as GABRA5, is a protein which in humans is encoded by the GABRA5 gene.[1][2]

Function[edit]

GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABAA receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABAA receptor. At least 16 distinct subunits of GABAA receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described.[1]

Subunit selective ligands[edit]

Recent research has produced several ligands which are moderately selective for GABAA receptors containing the α5 subunit. These have proved to be useful in investigating some of the side effects of benzodiazepine and nonbenzodiazepine drugs, particularly the effects on learning and memory such as anterograde amnesia. Inverse agonists at this subunit have nootropic effects and may be useful for the treatment of cognitive disorders such as Alzheimer's disease.

Agonists[edit]

Inverse agonists[edit]

See also[edit]

References[edit]

  1. ^ a b "Entrez Gene: GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5". 
  2. ^ Wingrove P, Hadingham K, Wafford K, Kemp JA, Ragan CI, Whiting P (February 1992). "Cloning and expression of a cDNA encoding the human GABA-A receptor alpha 5 subunit". Biochem. Soc. Trans. 20 (1): 18S. PMID 1321750. 
  3. ^ Ballard TM, Knoflach F, Prinssen E, et al. (2008). "RO4938581, a novel cognitive enhancer acting at GABA(A) alpha5 subunit-containing receptors". Psychopharmacology (Berl.) 202 (1–3): 207–23. doi:10.1007/s00213-008-1357-7. PMID 18936916. 
  4. ^ McCabe, L. L.; McCabe, E. R. B. (2013). "Down syndrome and personalized medicine: Changing paradigms from genotype to phenotype to treatment". Congenital Anomalies 53 (1): 1–2. doi:10.1111/cga.12000. PMID 23480351.  edit
  5. ^ van Niel MB, Wilson K, Adkins CH, et al. (2005). "A new pyridazine series of GABAA alpha5 ligands". J. Med. Chem. 48 (19): 6004–11. doi:10.1021/jm050249x. PMID 16162003. 
  6. ^ Chambers MS, Atack JR, Bromidge FA, et al. (2002). "6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists". J. Med. Chem. 45 (6): 1176–9. doi:10.1021/jm010471b. PMID 11881985. 
  7. ^ Chambers MS, Atack JR, Broughton HB, et al. (2003). "Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition". J. Med. Chem. 46 (11): 2227–40. doi:10.1021/jm020582q. PMID 12747794. 
  8. ^ Savić MM, Clayton T, Furtmüller R, et al. (2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Res. 1208: 150–9. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590. 

Further reading[edit]

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.